The effect of lean or obese mouse adipocyte on the mesenchymal-to-epithelial transition of MDA-MB-231 cells in 3-dimensional culture by Asante, Emmanuel
i 
 
The Effect of Lean or Obese Mouse Adipocyte on the Mesenchymal-to-Epithelial 
Transition of MDA-MB-231 Cells in 3-Dimensional Culture. 
By 
 
©Emmanuel Asante, BSc. (Hons.) 
 
A Thesis submitted to the School of Graduate Studies in partial fulfilment of the 
requirements for the degree of 
 
Master of Science 
Department of Biochemistry, Faculty of Science 









Obese breast cancer (BC) patients have at least 30% increased risk of death from 
BC compared to non-obese BC patients. This is because obesity is associated with larger 
tumor sizes and increased rates of metastasis. Obese BC patients respond poorly to 
treatment compared to non-obese patients, especially when diagnosed with the triple 
negative BC (TNBC) subtype. The reasons behind the poor treatment outcomes associated 
with obesity are not fully understood. The Christian Laboratory had previously established 
a novel 3-dimensional co-culture system that permitted the co-culture of adipocytes and 
TNBC cells in a manner that mimics an in vivo milieu. Using this system, I demonstrated 
that lean and obese mice white adipose tissue could induce a mesenchymal-to-epithelial-
transition (MET)-like effect in TNBC cells, thus furnishing the BC cells with properties 
that enable them to colonize and establish tumors in secondary organs. I have also shown 
that pro-MET factors are systemically secreted. Taken together this study suggests that 
adipose tissue has the potential to promote secondary tumor formation in lean and obese 
women. Further work is needed to determine if targeting the MET-like effect induced 
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CHAPTER 1: INTRODUCTION 
1.1 Breast Cancer 
Breast cancer (BC) is the most frequently diagnosed cancer and the leading cause of 
cancer related mortality among women globally. In 2018, about 2.1 million new cases were 
recorded worldwide and over 600,000 deaths occurred [1]. BC is ranked second to lung 
cancer as the leading cause of all cancer deaths [2]. BC survival rates vary geographically. 
About 80% of BC patients who reside in high income countries have a 5-year relative 
survival, compared to less than 40% of patients who live in poor or low-income countries 
[3]. This disparity can be attributed to lack of adequate early detection and treatment 
programs in low-income countries [4]. 
The pathoetiology of BC is not fully understood as a significant proportion of the 
disease develops sporadically [5]. However, several risk factors have been positively 
associated with the pathogenesis of the disease, include gender [6], age [7], race [8, 9], 
family history of the disease [10], body weight [11], genetic mutations [12], hormone 
replacement therapy [13], alcohol consumption [14], radiation exposure [15], and 
reproductive history [16]. The pathogenesis of BC can be understood by studying the 
anatomy of the female breast. 
The female breast is made up of the mammary gland, adipose tissue, and loose fibrous 
connective tissue [17]. The adipose tissue and the connective tissue make up the stroma 
that supports the mammary gland. The mammary gland is composed of lobules, the milk 
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producing unit, and the lactiferous ducts that drain milk to the nipple. Each lobule is 
comprised of alveoli, which are hollow cavities of luminal epithelial cells. A layer of 
supportive myoepithelial cells surrounds the luminal epithelial cells. The lactiferous ducts 
are also lined with epithelial cells that are supported by myoepithelial cells. BC arises when 
the cells of the lobule or the duct undergo a neoplastic transformation which may become 
invasive and metastatic or benign [18]. Cancers arising from the luminal epithelial cells are 
known as luminal cancers while those arising from the basal cells are termed basal cancers.  
There is an intermediate stage of hyperplasia prior to the complete neoplastic 
transformation of normal cells of the mammary gland [18]. The intermediate stage can be 
atypical or usual lobular or ductal hyperplasia. Atypical hyperplasia is characterized by 
abnormalities in number, shape size, appearance, and growth pattern of the cells of the duct 
or lobule [19]. However, usual hyperplasia is marked by an increase in the number of 
benign cells [19]. Hyperplastic lesions may progress to ductal carcinoma in situ (DCIS) or 
lobular carcinoma in situ (LCIS) [18]. In carcinoma in situ, the hyperplastic cells of the 
lobule and ducts are non-invasive and are separated from the normal microenvironment by 
the basement membrane and the myoepithelial cell layer [20]. The hyperplastic cells 
eventually become cancerous, and breach the integrity of the basement membrane and the 
myoepithelial cell layer, consequently enabling the cancer cells to invade into surrounding 
tissues where they further migrate to distal site via the lymphatic and blood streams thus 





Figure 1.1: A schematic representation of breast cancer initiation and metastatic 
cascade  
Genetic and epigenetic changes in the luminal and basal cells lead to the oncogenic 
transformation of cells thus making them hyperplastic and proliferative. The cancerous 
cells undergo epithelial-to-mesenchymal transition (EMT) and degrades the extracellular 
matrix (ECM) and basement membrane causing cancer cells to invade into the stroma. 
Consequently, the cancer cells migrate towards the nearest blood or lymphatic vessel where 
they intravasate into the vessel and are transported as circulating tumor cells to distal 
organs. Cancer cells extravasates from the blood vessel and undergo mesenchymal-to-
epithelial transition (MET) to colonize the brain, lungs and bone. Information was sourced 
from [21]. The figure was generated with Microsoft Powerpoint 365.  
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1.2 Subtypes of Breast Cancer 
BC is a heterogenous disease with different subtypes exhibiting distinct biological 
behaviours and clinical outcomes [22]. Broadly, the disease can be classified based on its 
histological or molecular profile [23]. The histological based classification is dependent on 
the histological features or morphology of the tumor and it categorizes the disease into two 
broad subtypes: in situ carcinoma and invasive carcinoma [19]. Depending on the growth 
pattern and the cytological phenotypes of the tumor, breast carcinoma in situ can be further 
subdivided into DCIS or LCIS [19]. The DCIS subtype also presents with distinct 
histological features and so far, five sub-groupings have been identified. These sub-
groupings include the comedo, cribriform, micropapillary, papillary, and solid types [24]. 
The invasive carcinoma displays a high degree of heterogeneity, and as such, breast 
carcinomas which fall under this group are further sub-categorized into infiltrating ductal, 
invasive lobular, ductal/lobular, mucinous (colloid), tubular, medullary and papillary 
carcinomas [19]. Infiltrating ductal carcinoma is the most common carcinoma in this sub-
group, accounting for 70-80% of all invasive carcinoma [23]. Infiltrating ductal carcinoma 
can be sub-stratified into well, moderately or poorly differentiated subtypes depending on 
factors such as nuclear pleomorphism, glandular/tubule formation and mitotic rate [25].  
 Although the histological classification system can be used in tumor staging and 
disease prognosing, it is not robust enough to predict patients’ response to targeted 
therapies [26]. This flaw was addressed by the adaptation of a molecular based 
classification in conjunction with the histological classification system. The molecular 
classification system stratifies BC based on the presence or absence of the expression of 
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progesterone receptor (PR), estrogen receptor (ER), human epidermal growth factor 
receptor 2 (HER2), and ki67 proliferation marker by the tumor [27]. The receptors are drug 
targets and its presence or absence on tumor cells can be used to predict patients who are 
likely to benefit from targeted therapy. The advent of microarray technologies for gene 
expression analysis and profiling has led to the discovery of additional unique BC subtypes, 
however these additional molecular subtypes do not have actionable drug targets at this 
time [23].  
BC subtypes under the current molecular classification scheme include the luminal-
like, HER2 enriched/positive, basal-like/triple negative breast cancer, and normal-like sub-
types [27]. The luminal-like subtype has two variants: luminal A and luminal B [28]. About 
40% of BC are of the luminal A subtype and they are characterized by the expression of 
ER and PR [23]. They have good prognosis and typically respond to the ER antagonist, 
tamoxofin [29]. The luminal B subtype is ER positive and can be HER2 positive or 
negative. They accounts for about 20% of the tumors and do not respond well to hormone 
therapies, thus making them more aggressive than the luminal A subtype [30]. The HER2 
enriched class comprises 10-15% of breast tumors [23]. It mostly affects younger women 
and can respond to the anti-HER2 drug, trastuzumab [31]. The triple negative breast cancer 
(TNBC) lacks the expression of ER, PR, and HER-2 and mostly affects young and 
premenopausal women. It accounts for about 15-20% of BCs. TNBC is highly metastatic 
and has no targeted therapy hence, it has the grimmest prognosis of all the molecular breast 
cancer subtype [32].  
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One of the major advantages of the molecular based classification of BC is that it 
paints a more accurate picture of the disease prognosis by identifying patients who are most 
likely to respond to targeted therapy and those who are better off receiving a more 
aggressive chemotherapeutic treatment. The table below summaries the molecular profile 













Luminal A 40 ER +/PR+ /HER2 - low Hormonal therapy 










15-20 ER- /PR - /HER2 - high Chemotherapy 
Normal-like 10 ER+ /PR + /HER2 - Low/intermediate Chemotherapy 
PR = progesterone receptor, ER = estrogen receptor, HER2 = human epidermal growth 




1.3 Tumour Heterogeneity of Breast Cancer 
Tumor heterogeneity relates to the idea that no two BCs are the same. It is the main 
cause of the variable therapeutic response and clinical outcome among BC patients. The 
two kinds of tumor heterogeneity include inter-tumor heterogeneity and intra-tumor 
heterogeneity [35]. Inter-tumor heterogeneity describes the variation in tumors of a given 
origin (e.g. breast) between patients, considering their histological features, molecular 
marker expression, biological behavior, and treatment outcomes [36]. Clear evidence of 
inter- tumoral heterogeneity in BC lies in the myriad of BC subtypes discussed in section 
1.2. Intra-tumor heterogeneity on the other hand describes the presence of a heterogeneous 
cell population within a particular tumor [37]. This kind of heterogeneity can be seen at the 
histological, biomarker, genetic, and epigenetic levels [37]. Some BCs can show up to two 
distinct morphologies upon histopathological examination (e.g. IDC and mucinous 
carcinoma [23]) while others may show ambiguous morphological features, for instance, 
an IDC tumor may exhibit lobular characteristics.  
Variations in breast tumor histology have been associated with specific genetic 
alterations  [38-40]. Variation in ER/PR or HER2 expression within cells of a given BC 
biopsy is a common phenomenon [41, 42]. A few models have been proposed to explain 
the origin of intra-tumor heterogeneity including clonal evolution and cancer stem cell. The 
clonal evolution model proposes that an entire tumor mass is formed from an evolving 
expansion of monoclonal or polyclonal population of the tumor cells [36]. The cancer stem 
cell model proposes that the different cell population with a tumor arose from a single 
precursor cell [36]. A notable challenge posed by tumor heterogeneity is therapeutic 
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resistance because tumors typically have subpopulations of unique cells which respond 
differently to a given chemotherapeutic. This varied response can lead to disease relapse 
after treatment as not all cells are effectively killed [43].  
1.4 Breast Cancer Metastasis 
Tumor metastasis is a highly complex process that enables the dissemination of the 
tumor cells from its origin to distal parts of the body where they can establish secondary 
tumors [44]. Tumor metastasis accounts for about 90% of breast cancer related morbidity 
and deaths [45]. The most common sites of BC metastasis include the bone, brain, lungs 
and the liver [46]. Rarely, the tumor can also spread to the extraocular muscle [47] and to 
the urinogenital regions of the body [48-50].  
Tumor metastasis is thought to be a multistep event which must be executed 
sequentially for tumor cells to successfully spread to distal sites. Broadly, the metastatic 
cascade can be broken down into four main processes: invasion, intravasation, 
extravasation, and colonization [21] (Fig 1.1). First, tumor cells dissociate from the primary 
tumor mass and undergoes an epithelial-to-mesenchymal transition (EMT), a process 
which enable them to invade the stroma and intravasate into blood or lymphatic vessels that 
then allows their transportation to distal organs [51]. Upon arriving at distal organs, the 
circulating tumor cells (CTC) then extravasate and undergo mesenchymal-to-epithelial 
transition (MET) to colonize distant organs [21]. 
1.4.1 Epithelial-to-Mesenchymal Transition 
  EMT is a biological process whereby polarized and adherent epithelial cells 
undergo biochemical and morphological changes that result in the loss of their baso-apical 
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characteristics and in the acquisition of mesenchymal cell phenotypes such as migratory 
capability, invasiveness, increased secretion on ECM components, and resistance to 
apoptosis [52]. EMT occurs in different biological contexts and is classified into type 1, 
type 2, and type 3. Type 1 EMT occurs in developmental processes such as implantation, 
embryogenesis, and organogenesis [53, 54]. Type 2 EMT is activated in response to tissue 
injury or trauma and is therefore associated with wound healing, fibrosis, and tissue 
regeneration [55, 56]. Type 3 EMT on the other hand, is associated with tumor progression, 
and metastasis [57]. Essentially, cancers hijack the EMT process to aid their metastatic 
effort. The remainder of this section shall expatiate on the type 3 EMT and BC metastasis.  
 The journey of a tumor cell from its origin to distal sites begins with its ability to 
invade into nearby tissues and blood vessels. It is hypothesized that this process is initiated 
when BC cells on the tumor margin undergo EMT to dedifferentiate from epithelial cells 
to mesenchymal cells [58]. This process is accompanied by the concomitant 
downregulation of E-cadherin, a protein that regulates cell-cell adhesion, and the 
upregulation of the expression of N-cadherin and vimentin [59]. The EMT process is under 
the regulation of the three main pathways: transforming growth factor beta (TGF-β), Notch 
and Wnt, although it can also be mediated by hypoxic condition in the tumor 
microenvironment (TME) [60]. The activation of these pathways leads to the upregulation 
of SNAIL, Zeb, and Twist [58]. The expression of these transcription factors results in the 
repression of E-cadherin [61]. Hypoxic TME induces EMT by causing changes in 
mitochondrial function which results in the activation of hypoxia-inducible factor 1 (HIF1) 
and expression of Zeb1 [58]. Additionally, previous studies have shown that hypoxic 
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conditions can induce EMT by blocking the activity of  glycogen synthase kinase 3 beta 
(GSK3β) [60]. 
 Upon the acquisition of invasive and migratory properties via EMT, metastatic BC 
cells then invade into surrounding tissues by degrading the basement membrane. The 
basement membrane serves as a physical barrier to restrict metastatic BC cells from 
invading into surrounding tissues [62]. EMT is accompanied by a surge in the production 
of matrix metalloproteinases (MMPs) by the tumor cells that degrade the basement 
membrane [63]. Following this, the tumor cells intravasate into the lymphatic and 
circulatory system where they migrate as CTC, either as single cells or as cluster of 
mesenchymal cells. The activation of membrane type-1 (MT1)-MMP and MT2-MMP 
enables the tumor cells to establish contact with endothelial cells thus aiding intravasation 
[64]. In addition, increased expression of vascular endothelial growth factor (VEGF) and 
MMPs in tumor cells enables them to breach the integrity of blood and lymphatic vessels 
during intravasation and extravasation [65]. 
1.4.2 Mesenchymal-to-Epithelial Transition  
 MET is the reverse process of EMT. During MET, epithelial cells that had acquired 
mesenchymal-like migratory characteristic lose this phenotype to regain their original 
epithelial characteristics [66]. Just like EMT, MET equally plays an important role during 
developmental processes such as implantation, kidney organogenesis, and somitogenesis 
[67-69]. However, in cancers it has been hypothesized that MET may play a critical role in 
the formation of secondary tumors, albeit the exact mechanisms are yet to be defined [66].  
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 While very few studies have demonstrated MET in in vivo conditions [70], the re-
expression of E-cadherin in secondary tumors cells has been proposed as a marker for 
detecting MET. This is because some secondary tumor cells tend to re-express E-cadherin 
following tumor establishment [71]. Yate and co-workers co-cultured mesenchymal human 
prostate cancer cells with hepatocytes to mimic liver metastasis [72]. They found that the 
expression of E-cadherin was upregulated in the prostate cancer cells upon contact with 
hepatocytes, thereby, indicating that the mesenchymal prostate cancer cells had acquired 
epithelial properties [72]. Yate and co-workers postulated that re-expressed E-cadherin 
facilitated cell-cell adhesion, a property which is instrumental in the establishment of 
secondary tumor [72]. In addition, Aokage et al., immunoassayed EMT and MET 
biomarkers such as E-cadherin, β‐catenin, and germinin in surgically resected specimens 
of metastatic tumors which were en route to the lungs via the lymphatic vessels [73]. The 
expression of E-cadherin, β‐catenin, and germinin was upregulated in the epithelial state 
and downregulated in mesenchymal state [73]. Aokage and colleagues found that tumor 
cells in the lymphatic vessels had weak expression of E-cadherin, β‐catenin, and germinin 
hence, indicating that the tumor cells were in a mesenchymal state [73]. However, the 
expression of the epithelial biomarkers were elevated in tumor cells in the lung 
parenchymal, therefore, suggesting the tumor cells had transitioned from a mesenchymal 
to epithelial state [73].  
1.5 Breast Tumour Microenvironment  
 The TME can be described as the milieu around a proliferating tumor. The TME is 
heterogeneous and it comprises the stroma, blood vessels, endothelial cells, cancer 
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associated fibroblasts (CAF), immune cells, infiltrating inflammatory cells, adipocytes, 
signalling molecules, and ECM components [74]. The TME is dynamic and undergoes 
changes as the tumor progresses. Under physiological conditions, the ductal system of the 
mammary gland is typically comprised of luminal epithelial cells, myoepithelial, 
fibroblasts, and an intact basement membrane/ECM. However, as tumorigenesis ensues, 
the ductal environment becomes infiltrated with immune cells, CAF, as well as bone 
marrow derived macrophages [75]. In addition, the basement membrane/ECM loses its 
integrity through the action of molecules such MMPs which are released in the stoma 
thereby permitting tumor cells to invade into the surrounding tissue [76].  
 Evidence shows that the stromal cells and tumors cells are intimately connected. 
Stromal cells can influence tumor cells behaviour via the secretion of ECM proteins, 
chemokines, cytokines and growth factors, consequently promoting the survival, 
proliferation, invasion and of tumor cells [77]. The different stromal cells interact with and 
affect BC cells differently. For instance, CAFs have been shown to secrete growth factors 
such as fibroblast growth factor (FGF), hepatocyte growth factor (HGF), TGF-β and 
stromal cell-derived factor-1 (SDF-1) which aid tumor cell proliferation [78-80]. In 
addition, CAF can promote proliferation, angiogenesis, invasiveness and tumor growth by 
secreting a variety of cytokines [81-83]. Some studies have also implicated CAF in the 
induction of EMT via paracrine TGF-β1 signaling [84, 85].  
 Adipocytes are prominent members of the TME and have also been implicated for 
their role in BC progression. Adiposity, in general, has been strongly correlated with poor 
clinical outcomes among BC patients. BC cells co-cultured with cancer associated 
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adipocytes have exhibited increased invasion and migration in in vitro and in vivo 
conditions [86]. Evidence also shows that mature adipocytes can induce EMT-like changes 
in BC cells thus promoting tumor metastasis [87]. Adiponectin secreted by adipocytes has 
also been shown to enhance the growth and survival of breast tumors [88].  
 The ECM can also influence tumor behaviour. The main components of the ECM 
include fibronectin, collagens, laminins, glycoproteins, and polysaccharides [89, 90]. 
Tumor progression is accompanied by an increase in ECM collagen, causing the ECM to 
undergo remodeling to become stiffer [91]. A collagen-rich and stiff TME has been shown 
to trigger the upregulation of oncogenic mRNAs and signaling pathways that promote 
tumor proliferation and invasion [92-94]. Angiogenesis, immune cell infiltration, and 
tumor growth have all been linked to ECM rigidity [95]. In addition, one study found that 
BC patients with collagen-rich stiff tumors are less likely to respond to neoadjuvant 
chemotherapy than patients with softer tumors [96]. Together, these data show a stiffer 
ECM can enhance breast tumor progression. 
1.6 Obesity and Breast Cancer Progression 
Obesity, crudely defined as body mass index (BMI) > 30 kg/m2, is a major public health 
issue in different countries around the globe [97]. A 2013 study that assessed the global 
prevalence of obesity showed that about 36% of men, 38% of women, and 23% of children 
were either overweight or obese [98]. The global incidence of obesity is expected to reach 
approximately 20% by the year 2025 if preventive measures are not properly enforced [99].  
Obesity is strongly associated with different pathological conditions such as 
hypertension, type 2 diabetes mellitus, cardiovascular disorders, and cancer [100]. With 
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respect to cancer, more than 40% of cancer patients are either overweight or obese at the 
time of diagnosis [101, 102]. In addition, obesity has been identified as an independent risk 
factor for BC [103]. Women who are obese have a 30% increased risk of death from BC 
compared to non-obese women [104]. Of note, post-menopausal obese women are at an 
increased risk of death from ER or PR positive BC while obese pre-menopausal women are 
most likely to die from triple negative breast cancer [105]. Obesity is associated with larger 
tumor sizes and increased rates of metastasis [106, 107]. Furthermore, obese breast cancer 
patients have poor treatment outcomes as they do not respond well to treatment compared 
to non-obese patients, especially those with TNBC [105, 108].  
The connecting piece between BC progression and obesity is the adipose tissue. 
Adipose tissue can be described as a multifunctional and metabolically active endocrine 
organ. It stores excess lipids as triglycerides and secrete a variety of adipokines, cytokines, 
chemokines and hormone-like factors that regulate different physiological processes such 
as glucose and lipid metabolism, inflammatory response, insulin sensitivity and vascular 
endothelial function [109]. There are two types of adipose tissue in the body, namely brown 
adipose tissue (BAT) and white adipose tissue (WAT). BAT is involved in thermogenesis 
and thermoregulation particularly in neonates [110]. It accumulates around the kidney and 
adrenal glands and small amounts can be found on the scapular. The amount of BAT 
typically decreases within the first week of birth [110]. WAT depots are widely distributed 
around the body and can be categorized into subcutaneous WAT and visceral WAT [109]. 
Subcutaneous WAT is found underneath the skin where it guards against dermal infections, 
acts as an insulator to prevent body heat loss, and acts as a cushion to absorb external 
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mechanical stress [111]. Visceral WAT resides in the abdominal, thoracic and pelvic 
cavities and surround vital organs such as the heart, omentum, kidney, and gonads [111].  
The WAT secretes a number of bioactive molecules. In the lean state they secrete anti‐
inflammatory cytokines such as interleukin (IL) - 4, IL‐10, IL‐13, and TGF‐β1, and 
adiponectin [112]. However, in the obese state, WAT suffers system-wide chronic 
inflammation secondary to excessive deposition of lipids and expansion of the adipocyte 
[111]. This results in the activation of the nuclear factor kappa B (NF‐κB) pathway and 
elevated secretion of leptin, as well as pro-inflammatory cytokines such as IL‐1β, IL‐6, and 
IL‐8, tumor necrosis factor alpha (TNF‐α) and VEGF [113]. Furthermore, elevated levels 
of pro-inflammatory cytokines are strongly associated with increased cancer risk and tumor 
progression [112]. In particular, elevated levels of IL-6 can promote tumor proliferation, 
angiogenesis, EMT, and drug resistance in breast cancer [114]. Of note, obesity is linked 
to visceral metastases [115] and adipocytes from visceral WAT have enhanced effects on 
EMT of BC cells compared to those from subcutaneous WAT [116]. In summary, obese 
WAT creates a pro-oncogenic atmosphere which also contribute to poor prognosis in BC 
patients.  
1.7 Model Systems 
1.7.1 Mouse Model of Obesity 
 Animal models of obesity can be broadly categorized into genetic models and diet-
induced obesity (DIO) models [117]. The most common genetic models feature rodents 
(rats and mice) with a spontaneous monogenic mutation or genetically engineered mutation 
in the leptin pathway or leptin receptor [118]. The first monogenic model to be described 
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was the ob/ob mouse which was serendipitously discovered by the Jackson Laboratory in 
1949 [119]. The ob/ob mouse had a spontaneous single base deletion on the leptin gene and 
were unable to produce leptin [120]. Leptin is secreted by adipose tissue and it plays a 
critical role in appetite regulation. Mice which lack leptin have an insatiable appetite and 
become morbidly obese from hyperphagia [121]. Ob/ob mice suffer obesity related co-
morbidities such as impaired glucose intolerance, insulin resistance, and hyperglycemia 
[122]. Other genetic models which relate to the leptin pathway are those that have mutations 
on the leptin receptor. Although leptin is secreted, these models do not respond to it thereby 
resulting in hyperphagia and consequently obesity. Examples of these model include db/db 
mouse, Zucker rat, ZDF rat, and Koletsky rat [118].  
 DIO models are generated by feeding rodents high fat diet (HFD), often ad libitum, 
causing them to gradually gain weight until they become morbidly obese. There is a school 
of thought that DIO models closely mirror obesity in humans therefore making them more 
preferable for obesity related studies than genetically induced obesity models [117, 123]. 
Although Sprague Dawley rats, Long Evans rats, Sand mice, spiny mice, and AKR mice 
strains are susceptible to DIO, the most commonly used animal is the C57BL/6N mouse. 
Evidence shows that C57BL/6N mice on high fat and carbohydrate diet present with 
metabolic abnormalities that parallel metabolic syndrome in humans [124]. In addition to 
obesity, the mice develop hyperinsulinemia, hyperglycemia, and hypertension [124]. It 
usually takes 16-20 weeks for C57BL/6N mice on a HFD to become overtly obese such 
that their body weight is 20-30% higher than control chow-fed C57BL/6N mice [125]. One 
notable disadvantage of DIO model is that there is no single standardized HFD, although 
18 
 
some studies use 45 or 60 kcal% fat diets from Research Diets Inc [126-129]. Pure fat diet 
supplement with regular chow is an alternative but a less commonly used diet for DIO 
models [117]. 
1.7.2 Three-Dimensional Cell Culture Model 
Cell cultures have become an indispensable tool for studying different physiological 
and pathological processes in vitro. A number of ground-breaking discoveries in 
biosciences would not be possible without cell culture. There are two main kinds of cell 
culturing techniques: the conventional 2-dimensional (2D) monolayer culture and 3-
dimensional (3D) culture. In 2D culture, cells grow in monolayer on a flat rigid substrate, 
while in 3D culture, cells grow in aggregates or spheroids on a scaffold or matrix. The main 
advantage of 3D culture over 2D culture is that cells grown in 3D exhibit features that are 
similar to the complex in vivo environment [130]. The unique characteristics of 3D grown 
cells are attributed to the scaffold/matrix on which they grow [130]. The scaffold/matrix 
can be biologically or synthetically derived. The most common commercially available 
matrices of biological origin include BD MatrigelTM basement membrane matrix (BD 
Biociences), Cultrex® basement membrane extract (BME; Trevigen), and hyaluronic acid 
[131]. Synthetically derived scaffold includes polyethylene glycol, polyvinyl alcohol, 
polylactide-co-glycolide, and polycaprolactone [131]. These scaffolds and matrices are 
enriched with substances such as laminin, fibronectin, and collagen, which make them 
mimic an in vivo extracellular matrix (ECM), thereby providing a more realistic and 
biologically active milieu for cells to interact with each other, proliferate, differentiate and 
carry processes which may not be observed in a 2D culture [130].  
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 Due to its in vivo semblance, 3D culture models have been applied in different 
research fronts such as drug testing and pharmacological screening, gene and protein 
expression studies and cancer research [132-135]. In cancer research, 3D models have been 
employed in studying tumor cell signalling, tumor cell-ECM interaction, invasion, 
metastasis and angiogenesis [130]. In addition, features of tumor spheroids grown in 3D 
such as apicobasal polarization of cells, and acini-like structure formation have been shown 
to parallel that of in vivo tumors [136]. 
 The utility of 3D culture models in the study of breast cancer progression have been 
explored [137-139]. One of the earliest studies that employed 3D culture models in breast 
cancer research was performed by Kenny and co-workers [140]. In this study, they 
compared the morphological characteristics of different breast cancer cell lines cultured in 
3D, in the presence of an extracellular matrix, to those cultured in conventional 2D. The 
study showed that 3D cultured breast cancer cells can form one of four distinct colony 
morphologies: stellate, grape-like, round or mass-like structures [140]. These colony 
morphologies are dependent on the state of differentiation of the BC cells. For instance, 
mesenchymal breast cancer cell lines such as MDA-MB-231 cells formed stellate colonies 
with migratory spiky terminals in 3D culture, while epithelial cell lines such as MCF-7 
formed robust and stable round/mass-like colonies [140, 141]. They also found that the 
gene and protein expression profiles of the 3D cultured cells differed from those cultured 
in 2D and correlated with the respective colony morphologies. Importantly, EMT and MET 
processes are more accurately modeled in 3D culture systems in comparison to 2D cultures 
[142]. Of note, the Christian laboratory established a novel 3D co-culture model which can 
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be used to co-culture breast cancer cells and mature adipocytes thus using a laminin rich 
ECM [143]. This model can be used to study how breast cancer cells interact with the ECM 
as wells as adipocytes, which are essential components of TME.  
1.8 Rationale and Hypotheses 
Numerous studies have established a clear link between obesity and breast cancer 
progression [144-147]. Obese premenopausal breast cancer patients tend to have a more 
aggressive disease course and may develop resistance to therapy especially when diagnosed 
with TNBC [105, 148]. The mechanisms underlying obesity-associated tumor progression 
remain largely elusive. Adipocytes are abundant in the breast TME and have been shown 
to fuel tumor growth and metastasis in multiple ways, including promoting EMT, as well 
as secreting altered levels of signalling molecules such as proinflammatory cytokines, 
adipokines, proangiogenic factors, and ECM proteins [149, 150]. Moreover, data from the 
Christian laboratory show that mesenchymal MDA-MB-231 TNBC cell line acquires 
epithelial phenotypes when co-cultured in 3D culture with mature adipocytes, in the 
presence of laminin-rich Matrigel [143]. In addition, evidence shows that this process can 
be, at least partially, mediated by factors secreted by adipocytes. This, therefore, suggests 
that adipocytes may play a role in MET-mediated secondary tumor establishment. Taken 
together, it can be surmised that the key to elucidating the mechanisms of obesity-induced 
tumor aggression and metastasis lies in understanding how adipocytes, especially in the 
obese state, interact with tumor cells.  
 I hypothesize that: 
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1. Adipocytes from obese mice, via the secretion of a pro-MET factor(s), will 
enhance MET-like changes in MDA-MB-231 TNBC cells, with potential 
differences between visceral and subcutaneous WAT, and bone marrow adipose 
tissue depots, when compared to adipocytes from lean mice. 
2. Pro-MET factors are systemically secreted and serum from obese mice will 
promote MET-like changes in MDA-MB-231 TNBC cells more strongly than 
serum from lean mice. 
Research Objectives 
1. Determine the effect of lean or obese mouse subcutaneous or visceral WAT on the 
MET of MDA-MB-231 cells in 3D culture. 
2. Determine the effect of lean or obese mouse bone marrow adipocytes on the MET 
of MDA-MB-231 cells in 3D culture. 
3. Determine the effect of serum from lean or obese mouse on the MET of MDA-




CHAPTER 2: MATERIALS AND METHOD 
2.1 Cell Lines   
 MDA-MB-231 cells were obtained from American Type Culture Collection 
(ATCC), (Maryland, USA) and maintained in complete media (Roswell Park Memorial 
Institute (RPMI) 1640 Medium (Life Technologies, Burlington, ON) supplemented with 
10% fetal bovine serum (FBS) (Gibco - Life Technologies) and 1% penicillin-streptomycin 
(Life Technologies)). Cells were confirmed to be mycoplasma-free using the MycoAlert™ 
Plus Mycoplasma Detection Kit from Lonza (Basel, Switzerland). The cells were 
authenticated by Short Tandem Repeat (STR) profiling by The Centre for Applied 
Genomics (The Hospital for Sick Children, Toronto, Canada). Cells were used up to 15 
passages after initial thawing.  
2.2 Animal Care and Experimentation  
All animal procedures were approved by the Institutional Animal Use and Care 
Committee of the Memorial University of Newfoundland (MUN) (Protocol ID: 17-02-SC). 
Animal handling and experimentations were carried out in strict accordance with the 
guidance and recommendations of the Canadian Council on Animal Care. 
Five-week-old female C57BL/6N mice were obtained from Charles River 
Laboratories (QC, Canada). Mice were housed in the animal care facility at MUN under 
ambient conditions of temperature, relative humidity, and 12 hours light/dark cycle. Mice 
had access to standard rodent pellet diet and water ad libitum for a one-week 
acclimatization period. After this time, mice were randomly paired and stratified into two 
groups: one group was placed on low-fat diet (LFD) (10% fat by kCal, D12450J, with 
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matching sucrose to D12492; Research Diets, Inc., New Brunswick, NJ) and the other on 
high-fat diet (HFD) (60% fat by kCal, D12492; Research Diets, Inc., New Brunswick, NJ). 
Mice were maintained on these diets ad libitum for 10 weeks and their body weight were 
measured weekly. At week 10, the body weight of mice on HFD was significantly higher 
than that on LFD (Fig 2.1). 
On the tenth week, mice were anesthetized using isoflurane and approximately 1 ml 
of blood was collected by cardiac puncture [151]. Serum was separated from whole blood 
after incubating the sample at 37°C for 1 h followed by centrifuging the clotted blood at 
10,000 x g for 10 min at 4℃ [152]. Collected serum was aliquoted and stored at -80 ℃ for 
long-term use. Mice were euthanized by cervical dislocation and peri-uterine (visceral) and 
inguinal (subcutaneous) white adipose tissue (WAT), tibia and femur were isolated. WATs 
were weighed and placed in transport buffer (1x phosphate buffered saline [PBS] (137 mM 
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, and pH 7.4), 5.5 mM glucose, 1% 
penicillin-streptomycin) at room temperature while the tibia and femur were placed in 1x 
PBS on ice. The specimens were transported immediately to the biosafety cabinet for 

























Figure 2.1: Female C57BL/6N mice becomes obese after 10 weeks on high fat diet.  
Body weight of C57BL/6N mice fed low fat diet or high fat diet for 10 weeks. Values are 
means ± SD. n = 6. Differences between means were determined by repeated measure one-




2.3 Organotypic Culture of White Adipose Tissue  
Peri-uterine and inguinal WAT (200 mg, 400 mg, or 800 mg) were washed briefly 
in a sterile dish with sterile 1x PBS containing 1% penicillin-streptomycin. Tissue samples 
were minced into smaller fragment using a sterile razor and washed several times with 1x 
PBS over a 70 µm nylon mesh. Then, 80 µl of Matrigel (basement membrane matrix; 
growth factor reduced, phenol red free, Cat# 356231, 9.1 mg/ml, BD Bioscience, New 
Jersey, USA), which was cooled on ice, was pipetted into a 24-well plate and incubated at 
37℃ for 30 min. The tissue fragments were then embedded in the semi-solid Matrigel and 
incubated for an additional 15 minutes at 37 ℃. This procedure was used to prevent the 
tissue fragments from floating during culture and provide additional laminin-rich ECM. At 
this time, 1 ml of mammary epithelial basal media, (Promo Cell, Heidelberg, Germany) 
containing epidermal growth factor (10 ng/ml), insulin (5 μg/ml), hydrocortisone (0.5 
μg/ml), and bovine pituitary extract (0.4%) (3D culture medium) was added to the wells 
and incubated at 37℃ and 5% CO2. The WAT explants were cultured for 48 h after which 
time conditioned media (CM) was collected. Fresh media was added to the WAT explants 
and they were cultured for an additional 48 hours.  
2.4 Bone Marrow Mesenchymal Stem Cell Isolation and Adipogenic Differentiation  
 Bone marrow mesenchymal stem cells were isolated as previously described [153]. 
Briefly, tibia and femur were washed twice with 1x PBS to remove residual soft tissue and 
blood cells. Both ends of the bones were cut off and the bone marrow was flushed out with 
complete RPMI 1640 Medium using a 23 G needle fitted on a 5 ml syringe. Cell clumps 
were broken up by slowly pulling the clumps up and down the syringe. Single-cell 
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suspensions was made by filtering cells through a 70 µm nylon mesh. Isolated cells were 
placed in a 10 cm dish containing 10 ml of complete media and incubated for 48 h at 37℃ 
in 5 % CO2 incubator. After 48 h, non-adherent hemopoietic cells were removed from the 
adherent mesenchymal cell layer. The adherent mesenchymal cells were washed twice with 
1x PBS and cultured until they were 70-90% confluent, approximately 72 h. Cell were 
removed from the plate with 0.25% trypsin and 50,000 cells/ml were plated in the wells of 
a 24-well plate.  
Bone marrow stromal cells were maintained in complete media until they reached 
confluency, after which they were treated with and incubated in preadipocyte 
differentiation medium from Zenbio™ (Cat# DM-2) (DMEM / Ham’s F-12 (1:1, v/v),  
HEPES pH 7.4, FBS, biotin, pantothenate, human insulin, dexamethasone, 3-isobutyl-1-
methylxanthine (IBMX), peroxisome proliferator-activated receptor gamma (PPAR) 
agonist, penicillin, streptomycin, amphotericin B) for 7 days. Adipocytes were confirmed 
to be differentiated by visual confirmation of lipid droplet accumulation in > 40% of the 
cells. Differentiated bone marrow adipocytes (BMA) were then overlaid with 110 µl of 
Matrigel matrix and incubated for 1 h at 37 ℃. At this time, 1 ml of 3D culture medium 
with 2% Matrigel was added and the cells was cultured for 4 days with CM collected and 
replaced every 48 h.  
2.5 Oil Red O Staining 
 On the 7th day of adipogenic differentiation, BMA were stained with 500 ml of 
0.36% Oil Red O (Millipore, Massachusetts, USA) in 60% isopropanol for 10 min. Excess 
Oil Red O stain was removed by washing the wells three times with 1 ml of 1x PBS. Images 
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were captured at 20x using the Leica DMIL LED inverted microscope and analyzed with 
Infinity Analyse and Capture Software, version 6.5.  
2.6 3-Dimensional (3D) Culture   
The 3D culture was performed as previously described with slight modifications 
[143]. Briefly, 70 µl of Matrigel was placed in an 8-well culture slide (Cat# 354118, 
Corning-Life Science, New York, USA) and incubated for 1 h at 37℃ to allow it to solidify. 
CM from WAT or BMA were mixed with fresh 3D culture medium containing 2% Matrigel 
at a ratio of 1:1. MDA-MB-231 cells (6,750 cells total) in 500 µl of the diluted CM or 3D 
culture medium were then overlaid on the solidified Matrigel in the chambered slide. MDA-
MB-231 cells were grown for 48 h to allow colony formation. Diluted CM and 3D culture 
medium were replenished after 48 h and the cells were fixed on the 5th day with 4% 
paraformaldehyde for 20 minutes at room temperature. 
For 3D culture with serum, 6,750 MDA-MB-231 cells in 500 µl of 3D culture 
medium containing 2% Matrigel were overlaid on the solidified Matrigel. Varying amounts 
of serum (2 µl, 5 µl and 25 µl) obtained from lean or obese mice were added to 500 µl of 
the 3D culture medium. The cells were incubated for two days at which point the media 
were replenished, and the treatment repeated. Cells were incubated for an additional 2 days 
and fixed on the 5th day.  
2.7 Immunofluorescence (IF) Staining  
Following fixation, cells were permeabilized with 1x PBS containing 0.5% Triton 
X-100 for 10 minutes at 4 °C, then washed 3 times with PBS-glycine (100 mM glycine in 
1x PBS) and blocked with 10% donkey serum (Cat# D9663, Sigma-Aldrich, St. Louis, MO, 
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USA) in IF buffer (0.1% BSA, 0.2% Triton X-100, 0.05% Tween 20, 1x PBS) (blocking 
buffer) for 1 h at room temperature. Primary antibodies were diluted, as detailed below, in 
blocking buffer, incubated with cells overnight at 4 °C followed by detection with 
appropriate secondary antibody. Before and after secondary staining cells were washed 
three times with 300 µl of IF buffer. Cells were then stained with 4′,6-diamidino-2-
phenylindole (DAPI) (Life technologies) for 15 minutes at room temperature and washed 
one time with 1x PBS. The chambers were gently separated from the slide according to the 
manufacturer’s protocol and excess 1x PBS was gently wiped off with a Kimwipe. An even 
bead of silicone sealant (GE, Boston, MA, USA) was applied around the Matrigel layer to 
avoid compression of co-cultures by coverslips. Prolong Gold (Life Technologies) was 
used for mounting slides, coverslips applied, and the slides were placed in a dark at room 
temperature to dry overnight.  
Primary antibodies and dilutions used were as follows: vimentin (mouse) (1:200; 
Cat #V2258; Sigma-Aldrich, St. Louis, MO, USA), E-cadherin (mouse) (1:200; Cat 
#610181; BD Biosciences, Franklin Lakes, NJ, USA), Claudin7 (rabbit) (1:200; Cat 
#AB27487; Abcam, Cambridge, UK), CD24 (1:100; Cat #NBP1–46390; Novus 
Biologicals, Littleton, CO, USA), and Ki67 (mouse) (1:100; Cat #M724029–1; Dako, 
Denmark). Secondary antibodies used were AlexaFluor-647 anti-rabbit (Cat #711–605-
152; Jackson Immunoresearch laboratories, West Grove, PA), and DyLight 594 anti-mouse 
(NBP1–75617; Novus biologicals). The slides were imaged using the 20X objective with 




2.7.1 Assessment of background staining due to non-specific binding of antibodies  
To test for possible background staining that may occur due to non-specific binding of 
antibodies to endogenous Fc receptors or otherwise non-specifically, MDA-MB-231 cells 
were incubated with mouse IgG isotype and rabbit IgG isotype antibodies that matched the 
isotype of the staining antibodies to be used. This was followed by secondary antibody 
staining with DyLight 594 anti-mouse and AlexaFluor-647 anti-rabbit, respectively. 
Vimentin is expressed by MDA-MB-231 cells [154]; therefore, as a positive control, MDA-
MB-231 cells were stained with anti-vimentin primary antibody followed by DyLight 594 
anti-mouse secondary antibody. As expected, signals for vimentin staining in MDA-MB-
231 cells were detected (Fig. 3.1). No signal was detected in cells stained with mouse IgG 
isotype or rabbit IgG isotype antibodies indicating the absence of non-specific background 








Figure 2.2 Background staining due to non-specific antibody binding was not detected  
Representative images of MDA-MB-231 cells stained with: A) anti-vimentin followed by 
Dylight 594 anti-mouse secondary antibody. B) mouse IgG isotype control followed by 
Dylight 594 anti-mouse secondary antibody. C) rabbit IgG isotype control followed by 




2.8 Image Analysis  
Colony morphologies were assessed by analysis of circularity using ImageJ v.1.52a 
[155]. Structures present in five images per replicate (minimum 10 structures per replicate) 
were traced manually and the circularity measurement was obtained. A circularity value of  
> 0.7 was classified as round/mass-like, 0.7–0.2 was classified as grape-like, and < 0.2 was 
classified as stellate as reported previously [143]. Protein expression was analyzed using 
ImageJ by measuring the intensity of fluorescence of the whole image. Integrated density 
(IntDen) was determined to capture the total fluorescence of each marker. Background was 
subtracted by taking measurements of selected areas where cells were absent as observed 
from the respective bright field images. The total fluorescence intensity of each marker was 
determined by normalizing IntDen of each marker to IntDen of DAPI and then the relative 
IntDen values of each marker per condition was determined relative to the control. 
2.9 Statistical Analysis  
 Statistical analyse were performed as indicated in figure legends. Differences were 
considered significant at p<0.05. Data were analyzed using GraphPad Prism Version 




CHAPTER 3: RESULTS 
3.1 Mouse white adipose tissue causes MET-Like changes in mesenchymal MDA-
MB-231 TNBC cells grown in 3D culture  
To assess the effect of mouse WAT on the colony morphology of mesenchymal 
TNBC cells grown in 3D, 400 mg of peri-uterine (subcutaneous) and inguinal (visceral) 
WAT were isolated from lean and obese mice and cultured ex vivo to generate white 
adipose tissue-conditioned media (WAT-CM). As expected, MDA-MB-231 cells grown in 
3D culture without WAT-CM maintained their characteristic stellate morphology in 3D 
culture (Fig. 3.1A). In contrast, cells grown with WAT-CM acquired a mixed population 
of stellate, grape-like and round/mass-like colony morphologies in a manner that was 
dependent on both depot and obesity (Fig.3.1A). The lean and obese mouse subcutaneous 
WAT had similar effects on the morphological alteration of MDA-MB-231 cells in 3D 
culture. Both caused a significant decrease in the proportion of stellate colony in 
comparison to control, with 60% and 20% of the cell colonies acquiring grape-like and 
round/mass-like morphologies, respectively. The lean mouse visceral WAT had the least 
effect on the colony morphology of the MDA-MB-231 cells, with 60% of the colonies 
retaining their characteristic stellate morphology, and only 30% and 10% of the colonies 
acquiring grape-like and round/mass-like morphologies, respectively. The obese mouse 
visceral WAT, on the other hand, had similar effects, as the lean and obese mouse 
subcutaneous WAT with 29% of MDA-MB-231 cells retaining their stellate colony 
morphology, while 58% and 13% of the colonies had acquired grape-like and round-like 
morphologies, respectively.  
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While both lean and obese mouse subcutaneous and visceral WAT could cause 
mesenchymal MDA-MB-231 TNBC cells to acquire an epithelial-like morphology in 3D 
culture, the difference actually lies in the adipose depot. Overall, the subcutaneous WATs 
(both lean and obese) were most potent in inducing the morphology changes, but the 





Figure 3.1: White adipose tissue (WAT) conditioned media alters the characteristic 
morphology of mesenchymal triple negative breast cancer cell line.  
(A) Representative images of MDA-MB-231 cells grown in a 3D culture with or without 
lean or obese subcutaneous or visceral adipose tissue conditioned media (CM). (B) Total 
percentages of structure shapes are shown as mean ± SEM and were computed from six 
biological replicates. Overall significance of the proportion of colony shapes between the 
groups was assessed by χ2 analysis, ****p<0.0001.  Significant differences between groups 
were determined by one-way ANOVA followed by Tukey HSD post hoc analysis. Different 
letters or symbols represent statistically different groups: a,b,cP < 0.05 for stellate, 1,2,3P < 
0.05 for grape-like, and α,β,Υ,θP < 0.05 for round/mass-like.  
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Having observed that mouse WAT-CM can cause mesenchymal MDA-MB-231 
cells to acquire epithelial colony morphologies in 3D culture, I next assessed the effect of 
WAT-CM on the expression of EMT biomarkers in order to determine if the morphological 
changes reflected an MET event. Immunofluorescence confocal microscopy was used to 
detect the expression of EMT protein markers in MDA-MB-231 TNBC cells cultured in 
3D with or without mouse WAT-CM. The expression of vimentin (a mesenchymal marker), 
E-cadherin and claudin-7 (epithelial markers), and CD24 (a stemness and an epithelial 
maker) was assessed [156].  
As expected, MDA-MB-231 cells cultured in 3D without WAT-CM expressed high 
levels of vimentin but had low or no expression of CD24, claudin-7, or E-cadherin (Fig 
3.2). WAT-CM from lean and obese mice caused a significant gain in the expression of 
CD24, claudin-7, and E-cadherin in MDA-MB-231 cells relative to control but had no 
effect on the expression of vimentin. There was no statistically significant difference in the 
expression of the individual biomarkers when comparing lean to obese mice WAT-CM 
(Fig. 3.2 C-D). Furthermore, while lean and obese mouse WAT-CM induced the expression 
of claudin-7 in MDA-MB-231 cells, its expression was lower in cells treated with obese 
mouse subcutaneous WAT-CM (Fig. 3.2D). Overall, these data show that both lean and 
obese mouse WAT-CM can induce the expression of epithelial biomarkers in mesenchymal 
MDA-MB-231 cells. A complete loss of the mesenchymal morphology and expression of 
vimentin coupled with a significant gain in the expression of claudin-7 and E-cadherin 
would have been an indication of a full MET. However, my results show that the expression 
of vimentin in MDA-MB-231 cells remained elevated even upon acquiring epithelial 
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morphology and protein expression, therefore suggesting that lean and obese mouse WAT-







Figure 3.2: Mouse WAT-CM induces the expression of epithelial biomarkers in 
mesenchymal triple negative breast cancer cell line grown in a 3D culture.  
Representative images of MDA-MB-231 cells cultured with or without lean or obese 
subcutaneous or visceral WAT-CM and co-stained for vimentin, CD24, and DAPI (A), or 
E-cadherin, Claudin-7 and DAPI (B). (scale bar = 100 µm). C and D are the relative 
expression of the respective markers, mean ± SEM (n=6 biological replicates). The average 
protein expression from five images per replicate were normalized to DAPI and analyzed 
relative to the control cultures. Significance was determined by Friedman test. If 




3.2 Mouse WAT-CM-induced MET-like changes in MDA-MB-231 cells is not 
dependent on the quantity of adipose tissue 
One of the phenotypic hallmarks of obesity is the overabundance of adipose tissue 
[157]. Previous studies have established that obesity favours tumor metastasis relative to 
the non-obese state [158-160]. Obesity can promote tumor metastasis via different 
mechanisms such as increased induction of EMT in tumor cells [161], therefore, WAT-
induced MET-like changes in 3D cultured MDA-MB-231 cells could be dependent on a 
qualitative change to WAT in the obese state, as well as the quantity of WAT present. Thus, 
I hypothesized that the greater the quantity of obese adipose tissue present, the stronger the 
MET-like effect would be. To test this hypothesis, MDA-MB-231 cells grown in 3D were 
treated with or without WAT-CM generated from an ex vivo culture of 200 mg or 800 mg 
of obese mouse subcutaneous or visceral WAT. I used obese WAT for this experiment 
because, approximately 500 mg of WAT can be isolated from the subcutaneous or visceral 
depots of a lean mouse. Since this quantity of WAT is not enough for the experiment, 
WATs have to be pooled from multiple lean mice to obtain enough quantity for the 
experiment.  
Similar to what was previously observed, the morphological analysis of the cell 
colonies formed post WAT-CM treatment revealed a mixed proportion of different colony 
morphologies (Fig 3.3A). Overall, there was a significant decrease in the proportion of 
stellate cell colonies and an increase in the proportion of grape-like colonies. For 
subcutaneous WAT-CM, cells in the 800 mg treatment group formed more grape-like 
colonies than those in the 200 mg treatment group. However, there was no significant 
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difference in the proportions of colony morphologies among cells treated with 200 mg or 
800 mg of the obese visceral WAT-CM. Of note, cells treated with 200 mg or 800 mg of 
subcutaneous WAT-CM formed significantly lower proportions of stellate colonies and a 
higher proportion of grape-like colonies in comparison to cells treated 200 mg or 800 mg 
of visceral WAT-CM. This suggests that the subcutaneous WAT-CM is more effective than 
the visceral WAT-CM in altering the characteristic morphology of MDA-MB-231 cells 
grown in 3D, unlike previous data which showed that the visceral WAT in the obese state 
was as effective as the subcutaneous WAT. Also, the proportion of round/mass-like 
structures formed in 200 mg or 800 mg WAT-CM treated cells (Fig. 3.3) was lower than 
that formed in 400 mg WAT-CM treated cells (Fig 3.1) possibly due to animal related 
biological variability.  
  An analysis of the EMT protein marker expression showed that both 200 mg and 
800 mg of subcutaneous and visceral WAT-CM can induce the expression of epithelial 
proteins in 3D cultured MDA-MB-231 cells with no effects on the expression of vimentin, 
a mesenchymal marker (Fig 3.4). While the expression of all the epithelial biomarkers were 
generally elevated in all the treatment groups, the expression of epithelial biomarkers were 
consistently lower in cells treated with 200 mg visceral WAT-CM Overall, there was no 
significant difference in the expression of the EMT biomarkers among cells cultured with 
200 mg or 800 mg of subcutaneous or visceral WAT-CM. Taken together, the data suggest 
that the adipose tissue induced MET-like change in 3D cultured MDA-MB-231 cells is not 










Figure 3.3: Effect of varied WAT masses on colony morphology changes of MDA-MB-
231 cells in 3D culture. 
 A) Representative images of MDA-MB-231 cells grown in a 3D culture with or without 
200 mg or 800 mg of obese moue subcutaneous or visceral adipose tissue conditioned 
media (CM). B) Total percentages of structure shapes are shown as mean ± SEM and were 
computed from six biological replicates. Overall significance of the proportion of colony 
shapes between the groups was assessed by χ2 analysis, ****p<0.0001. Significant 
differences between groups was determined by one-way ANOVA followed by Tukey HSD 
post hoc analysis. Different letters or symbols represent statistically different groups: a,b,cP 










Figure 3.4: Effect of varied WAT masses on the EMT biomarker expression of MDA-
MB-231 cells in 3D culture. 
 Representative images of MDA-MB-231 cells cultured with or without 200 mg or 800 mg 
of obese subcutaneous or visceral WAT-CM and co-stained with anti-vimentin, anti-CD24, 
and DAPI (A), or anti-E-cadherin, anti-Claudin-7 and DAPI (B). (scale bar = 100 µm). C 
and D are the relative expression of the respective markers, mean ± SEM (n=6 biological 
replicates). The average protein expression from five images per replicate were normalized 
to DAPI and analyzed relative to the control cultures. No groups were found to be 




3.3 Bone marrow-derived adipocytes induced an ambiguous morphology change in 
3D cultured MDA-MB-231 cells. 
 Between 60% and 75% of secondary breast tumors are initially detected in the bone 
[162], which is associated with a significant decrease in the 5-year survival rate among 
breast cancer patients [163]. Recent studies have demonstrated the role of bone marrow 
adipose tissue in the progression of breast cancer [164]. To test the effect of bone marrow-
derived adipocyte on MET of MDA-MB-231 cells, bone marrow mesenchymal cells were 
isolated from lean and obese mice and differentiated to mature adipocytes. During my 
initial experiments, I found that BMA degraded the basement membrane matrix (Matrigel); 
this rendered the 3D co-culture of BMA and MDA-MB-231 cells impossible since MDA-
MB-231 cells cannot be overlaid on a degraded Matrigel. I therefore employed the CM 
approach. The differentiated adipocytes were then used to generate bone marrow-derived 
adipocyte-CM (BMA-CM) which were subsequently used to treat 3D-cultured MDA-MB-
231 cells. Adipogenic differentiation of bone marrow mesenchymal stem cells were 
confirmed initially by visual inspection for lipid droplet accumulation in ≥ 40% of the cells; 
this was followed by Oil Red O staining of BMA (Fig 3.5 A). In subsequent experiments, 
successful adipogenic differentiation was confirm only by visual inspection for lipid 
accumulation.  
 Results from the first biological replicate of this experiment showed that BMA-CM 
from both lean and obese mice could alter the characteristic stellate morphology of MDA-
MB-231 cells in 3D culture, thus, causing them to adopt a grape-like or mass-like 
morphology (Fig 3.5 B). In addition, the results showed that BMA-CM had no effect on 
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the expression of any of the EMT biomarkers tested (Fig. 3.5 C). Specifically, there were 
no changes in the expression of vimentin and no signal was detected for the expression of 
epithelial biomarkers. However, results from three addition biological replicates were 
conflicting. Those experiments showed that BMA-CM does not induce a morphological 
change of MDA-MB-231 cells in 3D culture nor does it affect EMT biomarker expression 

























Figure 3.5: Bone marrow-derived adipocytes (BMA) from lean and obese mice 
induced ambiguous effects on the morphology of MDA-MB-231 cells in 3D culture.  
In the first biological replicate, BMA-CM caused MDA-MB-231 cells to acquire epithelial 
morphology, however, three additional biological replicates showed no effect. A) 
Representative images of Oil Red O staining of undifferentiated bone marrow 
mesenchymal stem cells (BMSC), lean, and obese mouse BMA. B) Brightfield and DAPI 
images of MDA-MB-231 cells exposed to normal media (control), or CM from lean or 
obese mouse BMA. Cells in this experiment acquired epithelial morphology upon CM 
treatment. C) Images of MDA-MB-231 cells cultured with or without BMA-CM and co-
stained with anti-vimentin, anti-CD24, and DAPI, or anti-E-cadherin, anti-Claudin-7 and 
DAPI. (scale bar = 100 µm). Images shown in C are corresponding antibody staining 
images of B. D) Representative images of MDA-MB-231 cells that maintained their 
characteristic morphology upon BMA-CM treatment (n=3). E) Corresponding antibody 





3.4 Lean and obese mouse serum alters the characteristic morphology of 
mesenchymal MDA-MB-231 TNBC cells in 3D in a dose-dependent manner and 
induces MET-like changes 
It was previously shown that adipocytes secrete a factor(s), in the presence of an 
extracellular matrix, that induces MET-like changes in mesenchymal triple negative breast 
cells [143]. Another study had also shown that fetal bovine serum can induce EMT in the 
non-malignant, BEAS-2B lung epithelial cell line, showing that pro-EMT factors may be 
systemically secreted into the serum [165]. To assess if a pro-MET-like factor(s) is secreted 
into systemic circulation, MDA-MB-231 cells cultured in 3D were treated with or without 
2 µl, 5 µl and 25 µl serum from lean or obese mice, corresponding to 0.4%, 1% and 5% of 
the culture medium, respectively.  
I found that serum from lean and obese mice caused a dose-dependent effect in the 
formation of cell colony morphologies in 3D culture. Specifically, more MDA-MB-231 
cells lost their characteristic 3D stellate morphology and adopted the epithelial grape-like 
or round-like morphologies as the volume of the serum was increased (Fig 3.6). Overall, 
both lean and obese mice sera induced colony morphology changes similarly in each 
treatment group albeit there was no significant difference.0mr Of note, 25 µl of lean or 
obese mice sera caused almost a complete loss of the stellate colonies with 48.3% and 
49.6% of the cells acquiring a grape-like and round/mass-like morphologies, respectively.  
Neither lean nor obese mice sera had an effect on the expression of vimentin in 3D-
cultured MDA-MB-231 cells, irrespective of the treatment volume (Fig. 3.7). In addition, 
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25 l of both sera induced a significant increase in the expression of CD24, and E-cadherin 
in mesenchymal MDA-MB-231 cells. Even though both lean and obese mice serum 
induced the expression of claudin-7 in MDA-MB-231 cells, there was no significant 
difference in the expression of the protein among the different treatment volumes. The 
expression of E-cadherin in cells treated with 25 µl of lean or obese mice sera was 
significantly higher than that of the cells treated with 2 µl of lean mouse serum. These data 
show that sera from both lean and obese mice can induce MET-like changes in 3D-cultured 
mesenchymal MDA-MB-231 cells. Also, the proportion of epithelial structures formed 
upon serum treatment is dependent on the amount of serum in the culture system. High 
amounts of lean or obese mice sera may cause MDA-MB-231 cells to completely lose their 
mesenchymal phenotype. Taken together, a pro-MET factor(s) may be present in systemic 
circulation, but it is not clear if the factor(s) is the same as that secreted by the adipose 
tissue.  
The 3D structures formed by mouse serum-treated MDA-MB-231 cells were 
slightly distinct than those formed by WAT-CM treated cells. This difference is more 
noticeable among the grape-like and round/mass-like structures. Firstly, in comparison to 
WAT-CM treated cells, serum treated cells formed more robust and dense structures in 
which cells appeared to be more interconnected with each other. In addition, the 3D 










Figure 3.6: Lean and obese mouse serum alters characteristic morphology of 
mesenchymal triple negative breast cancer cell line in a concentration dependent 
manner.  
Representative images of MDA-MB-231 cells grown in a 3D culture with 2 µl, 5 µl and 25 
µl of lean or obese mouse serum or no serum controls (scale bar = 100 µm). Total 
percentages of structure shapes are shown as mean ± SD and were computed from six 
biological replicates. Overall significance of the proportion of colony shapes between the 
groups was assessed by χ2 analysis, ****p<0.0001.  Significant differences between groups 
was determined by one-way ANOVA followed by Tukey HSD post hoc analysis. Different 
letters or symbols represent statistically different groups: a,b,c,dP < 0.05 for stellate, 1,2,3P < 









Figure 3.7: Lean and obese mouse serum induces the expression of epithelial 
biomarkers in mesenchymal triple negative breast cancer cell line grown in a 3D 
culture.  
Representative images of MDA-MB-231 cells cultured with or without lean or obese mouse 
serum and co-stained with anti-vimentin, anti-CD24, and DAPI (A), or anti-E-cadherin, 
anti-claudin-7 and DAPI (C). (scale bar = 100 µm). B and D are the average protein 
expression from five images per replicate which were normalized to DAPI and analyzed 
relative to the control cultures. Significance was determined by Friedman test. If 




Figure 3.8: Comparison of 3D structures formed by serum or WAT-CM treated 
MDA-MB-231 cells.  
Representative brightfield images of WAT-CM or serum treated MDA-MB-231 cells in 
3D culture. Images were selected to illustrate the structural differences between WAT-




CHAPTER 4: DISCUSSION 
4.1 Summary 
The purpose of this study was to determine the effects of lean and obese mice 
adipose tissues, from different depots, and sera on the MET of mesenchymal triple negative 
breast cancer cells in 3D culture. A previous study from our laboratory had shown that 
mature adipocytes, in the presence of an ECM, secretes a factor(s) that induces MET-like 
changes in mesenchymal TNBC cell lines. Given that obesity is associated with tumor 
progression, I hypothesized that: (1) adipose tissue from obese mice, via the secretion of a 
pro-MET factor(s), would enhance MET-like changes in MDA-MB-231 TNBC cells, with 
potential differences between visceral and subcutaneous WAT, when compared to adipose 
tissue from lean mice, (2) pro-MET factors are secreted into the blood, and (3) obese mouse 
serum will promote MET-like changes in MDA-MB-231 cells with a greater magnitude 
than the lean mouse serum. Surprisingly, I found that both lean and obese mouse 
subcutaneous or visceral WAT cause 3D-cultured MDA-MB-231 cells to acquire epithelial 
morphology and protein expression whereas the expression of the mesenchymal marker, 
vimentin, was unaffected. While the induction of epithelial protein expression was not 
depot dependent, the adipose depots affected morphological alteration differently. Lean and 
obese mouse subcutaneous WAT, and obese mouse visceral WAT, were more efficacious 
in inducing MET-like morphology changes in MDA-MB-231 cells, while lean visceral 
WAT had the least effect on the morphological changes. I have also demonstrated that pro-
MET factors secreted into the blood with both lean and obese mice sera promoted MET-
like changes in mesenchymal TNBC cells in a similar way. 
60 
 
4.2 Effects of lean and obese mouse WAT on MDA-MB-231 cells grown in 3D 
culture 
The 3D culture model utilized in the previous study from the Christian laboratory 
was designed such that differentiated 3T3-L1 adipocytes and breast cancer cells 
sandwiched a basement membrane matrix [143]. The basement membrane provides a 
physical medium through which the two different cells interact with each other. This 
approach was unsuccessful in my study as the in vitro adipogenic differentiation of mouse 
preadipocytes, which were isolated by stromal vascular fractionation of WAT, yielded low 
differentiation. Although WAT depot-specific properties are preserved in in vitro 
differentiated adipocytes, obesity associated characteristics such as increased pro-
inflammatory cytokine secretion and macrophage infiltration may be lost to the stromal 
vascular fractionation of WAT and subsequent induced differentiation [166, 167]. This led 
to the adaptation of an organotypic culture model in which mouse WAT was cultured ex 
vivo to generate WAT CM. TNBC cells grown in 3D on a basement membrane were then 
treated with WAT CM. This model permitted an indirect assessment of the effects of the 
WAT on the TNBC cells via the CM.  
Using this modified approach, I found that both lean and obese mouse subcutaneous 
and visceral WATs caused MET-like changes in mesenchymal MDA-MB-231 cells, as 
evidenced by their acquisition of epithelial morphology and protein expression. In general, 
no marked difference was observed in the MET induction capacity of lean and obese mouse 
WAT, however, the subcutaneous WAT and visceral WAT affected MET-like morphology 
changes in MDA-MB-231 cells distinctively. Both lean and obese mouse subcutaneous 
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WAT proportionately increased the “epithelialization” of MDA-MB-231 cells relative to 
the lean visceral WAT. Meanwhile, in the obese state, mouse visceral WAT induced the 
same magnitude of effect as the lean and obese mouse subcutaneous WAT. It is worth 
noting that subcutaneous and visceral WATs are morphologically and functionally distinct 
[168, 169]. They arose from different progenitor cells, and have a differential gene 
expression pattern [170, 171]. In addition, the two depots also have a distinct biomolecule 
and adipokine secretion profiles [168]. Therefore, the depot dependent MET-like 
morphological changes may be due to differential secretion of pro-MET factor(s) by the 
two depots, hence, reflecting the fundamental biological differences between subcutaneous 
and visceral WAT.  
 In principle, true MET is characterized by the following: a complete acquisition of 
epithelial morphology, downregulation of mesenchymal proteins, and upregulation of 
epithelial proteins [172, 173]. In this study, I found that even though the WAT upregulated 
the expression of epithelial biomarkers in MDA-MB-231 cells, the expression of vimentin, 
a mesenchymal biomarker, remained unaltered. Thus, MDA-MB-231 cells appeared to be 
in a hybrid mesenchymal/epithelial state. This was not in keeping with the previous study 
from the Christian lab which showed that mature adipocytes caused a significant 
downregulation of the expression of vimentin, while it upregulated the expression of 
epithelial biomarkers [143]. Of note, in that study, mature adipocytes were co-cultured with 
MDA-MB-231 cells in 3D for 5 days. This differs from the CM approach I adopted, which 
exposed MDA-MB-231 cells to fresh CM twice within 5 days. It is possible that the other 
cell types present in WAT are influencing the ability of adipocytes to induce an MET-like 
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change. Alternatively, a constant and uninterrupted supply of the pro-MET factor(s) in the 
culture system is crucial for initiating enough signal to downregulate the expression of the 
mesenchymal biomarker, which is lacking in a CM approach.  
A state of phenotypic duality in cancer cells have been previously described, 
particularly in cells undergoing EMT [178, 179]. Evidence shows that carcinoma cells can 
successfully metastasize to other organs without completely undergoing EMT [174, 175]. 
Tumor cells in the hybrid epithelial/mesenchymal state possess migratory and cell-cell 
adhesion properties tend to migrate as multicellular aggregates in the bloodstream of cancer 
patients [176-178]. These tumor cells have superior survival advantages than cells that had 
undergone complete EMT and are migrating as single cells [176, 179]. Cells migrating in 
clusters are more likely to survive anoikis en route to distal organs [180, 181]. In addition, 
they have been shown to be immuno- and chemo-resistant [179]. Thus, a hybrid tumor state 
can contribute to increased tumor aggression. The hybrid phenotype I found in my study 
was different from the previously reported phenotype, since MDA-MB-231 cells were 
originally mesenchymal and do not express epithelial biomarkers. They only acquired an 
epithelial phenotype after exposure to WAT CM and were potentially on course to a full 
MET. Gunasinghe and colleagues used an MDA-MB-468 xenograft model to demonstrate 
that BC cells undergoing local lymphovascular invasion could transition from a metastable 
state to an epithelial state [173]. They showed that tumor emboli in the lymphovasculature 
which co-expressed vimentin and E-cadherin gradually lost the expression of vimentin to 
predominantly express E-cadherin. This evidence supports the idea that the hybrid 
phenotype observed in my study could be a transitionary phase which might be followed 
63 
 
by the downregulation of vimentin possibly upon the amplification a MET activation 
signal. 
Although accumulating evidence indicates that the MET process plays as critical 
role in secondary tumor establishment, the underlying mechanism and regulatory factors 
remains largely unknown [70, 71, 173, 182]. The common denominator among evidence 
that supports MET mediated secondary tumor formation is the re-expression of E-cadherin 
in migrating tumor cells [71, 173]. E-cadherin belongs to a family of Ca2+-dependent cell 
adhesion molecules which mediate cell-cell adhesion and plays an important role in 
maintaining tissue integrity [21]. The expression of E-cadherin is reduced or lost prior to 
the initiation of tumor invasion and metastasis [21]. E-cadherin repression in tumor cells 
consequently triggers the activation of EMT induction machinery that promotes invasive 
and migratory phenotypes [21]. Hypermethylation of the E-cadherin promoter [183, 184], 
and hypoxia [185] are among the factors that repress the expression of E-cadherin in 
tumors. Transcription factors such as SNAIL, Slug, ZEB1, and ZEB2 can also repress E-
cadherin expression by binding to the E-box of the E-cadherin promotor [186]. WAT-
induced MET-like changes and E-cadherin re-expression in MDA-MB-231 cells could 
possibly be due to the inactivation of SNAIL, Slug, ZEB1, or ZEB2. Demethylation of the 
E-cadherin promoter could also be plausible mechanism. Further studies are needed to 
elucidate the exact mechanisms. 
One of the main goals of cancer therapeutics is to inhibit metastatic dissemination 
of cancer cells to distal organs since this is the major cause of mortality among patients 
[187]. Targeting key processes in the tumor metastasis cascade such as EMT/MET 
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represents a viable strategy for achieving this goal. In theory, targeting EMT could abrogate 
the migratory and invasive potential of the tumor thereby preventing the metastatic 
dissemination of tumor cells from their primary origin. Inhibiting MET could prevent tumor 
colonization in secondary organs. WAT derived pro-MET factor(s) could be a potential 
therapeutic target for inhibiting metastasis formation in both lean and obese TNBC patients. 
This therapeutic strategy could be combined with other established treatment regimens, 
such as chemotherapy, to help ameliorate the disease progression. 
4.3 Effects of lean and obese mice BMA on MDA-MB-231 cells grown in 3D culture 
 The bone is the most frequent site of metastasis in breast cancer patients [175]. Bone 
metastasis generally worsens the disease prognosis and presents with excruciating pain, 
bone fracture, hypercalcemia, and immobility [177]. Factors which promote bone 
metastasis remain elusive. For decades, Stephen Paget’s “seeds” and “soil” theory has been 
touted as a possible mechanism for bone metastasis [188]. This theory proposes that 
metastatic tumor cells (“seed”) only migrate to organs (“soil”) that provide a fertile milieu 
to support their growth and survival. The bone hosts a variety of cells such as mesenchymal 
stem cells, osteoclasts, osteoblasts, immune cells, and bone marrow adipocytes, which have 
all been implicated for their role in driving bone metastasis [189]. Recently, the bone 
marrow adipose tissue is gaining the spotlight as a key contributor to bone metastasis [189]. 
Herroon et al., showed that bone marrow adipocytes promoted prostate cancer growth via 
the secretion of fatty acids and activation of hypoxia inducible factor-1a [190]. 
Furthermore, bone marrow adipocytes have been shown to promote the growth of 
leukaemia cells via lipid transfer [191].  
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 Having established that WAT can induce MET-like changes in MDA-MB-231 cells 
and considering the potential role of MET in secondary tumor colonization, I investigated 
the effects of mice BMAs on the MET of MDA-MB-231 cells. The first replicate of this 
experiment showed that both lean and obese mice BMA could cause MET-like 
morphological changes in MDA-MB-231 cells with no effect on the EMT biomarker 
expression. However, results from three additional biological replicates showed that BMAs 
had no effect on the morphological alteration of MDA-MB-231 cells nor did it affect the 
expression of EMT biomarker. The reasons behind these conflicting findings are not clear. 
Of note, this experiment had some limitations. I generated CM from BMAs that were 
obtained from the adipogenic differentiation of bone marrow mesenchymal stem cells 
because it is technically challenging to isolate whole bone marrow adipose tissue or 
adipocytes from the mouse bone marrow. Although Oil Red O staining of the differentiated 
BMAs showed visible lipid droplets in all replicates, the proportion of lipid droplets varied 
highly with each experiment, possibly due to the heterogeneity of the bone marrow stroma 
and the variable population of isolatable mesenchymal cells in the bone marrow [192]. It is 
not clear if the proportion lipid droplets formed following adipogenic differentiation would 
correlate with the magnitude of MET-like effect in this instance. But logically, low 
adipogenic differentiation corresponds to low secretion of adipocyte-derived pro-MET 
factors into the CM. The conflicting findings may be resolved by exploring efficient models 
which utilizes intact bone marrow adipose tissue. 
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4.4 Effects of lean and obese mice sera on MDA-MB-231 cells grown in 3D culture 
 Different types of cells in the body, including adipocytes, actively secrete 
biomolecules such as hormones, lipids, and free proteins into the systemic circulation, 
which are often needed for a specific biological function. Since the blood serum is rich in 
these secreted biomolecules, I hypothesized that pro-MET factors are secreted into the 
blood and secondly, that obese mouse serum would induce MET changes in MDA-MB-
231 cells more strongly than the lean mouse serum. My results showed that pro-MET 
factor(s) are systemically secreted into lean and obese mice sera as both sera induced MET-
like changes in MDA-MB-231 cells. Interestingly, both lean and obese mice sera induced 
MET-like changes in a similar manner with dose-dependent MET-like changes in MDA-
MB-231 cells. The dose-dependent effect was more apparent in the morphological 
alteration of the cell colonies and in the induction of CD24 and E-cadherin expression.  
It is unclear if the serum-derived pro-MET factor(s) is the same as that secreted by 
the adipose tissue. A visual comparison of 3D structures formed by serum or WAT-CM 
treated MDA-MB-231 cells revealed a few morphological differences. Serum-treated 
MDA-MB-231 cells formed larger and more dense cell colonies compared to WAT-CM 
treated cells. The large, dense cell colonies formed by serum-treated cells may be due to 
increased cell proliferation. The blood serum is rich in growth factors such as platelet 
derived growth factors and epidermal growth factors which have been previously shown to 
stimulate tumor proliferation and growth [193-195]. To the best of my knowledge, no study 
has linked a serum derived factor or biomolecule to the induction of MET in tumor cells. 
So far only one study has linked the serum to EMT where Malm et al., showed that fetal 
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bovine serum can induce EMT in the non-malignant, BEAS-2B lung epithelial cell line 
[165]. More work needs to be done to identify and characterize serum derived pro-MET 
factors. 
 Systemically secreted pro-MET factors could have dire implications for metastatic 
breast cancer patients. This is because bloodborne pro-MET factors could interact with 
CTC and also perfuse distal organs like the brain, lung, and liver to prime the organs as 
well as the tumor cells for a MET-mediated metastasis. However, the identification of this 
factor opens a window of opportunity for therapeutic interventions that inhibit the activity 
of pro-MET factors to prevent secondary tumor formation. This is however contingent upon 
the identification the pro-MET factor and its mechanism of action. 
4.5 Conceptual Model for Adipose Tissue-Driven Secondary Breast Tumor 
Metastasis  
Obesity is characterized by the excessive deposition of adipose tissues in the body 
[196]. Numerous studies have established a clear link between obesity and breast cancer 
progression [144-147]. Adipocytes, being the predominant cell type in the breast tumor 
microenvironment, have been shown to fuel tumor growth and metastasis by secreting 
altered levels of signaling molecules such as proinflammatory cytokines, adipokines, 
proangiogenic factors and extracellular matrix constituents [149, 150]. Evidence also 
suggest that adipocytes can induce EMT, cause tumor invasion, and migration. My study 
and previous work done in the Christian lab [143] have consistently demonstrated that 
adipocytes can induce MET-like changes in mesenchymal TNBC cells via the secretion of 
an unknown factor(s). Thus far, our study sheds light on a previously unknown role of 
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adipocytes in the tumor progression cascade. Here, I will attempt to paint a broader picture 
of how adipocytes could be promoting breast tumor metastasis at all stages in the metastatic 
cascade (Fig. 4.1). 
First, adipocytes interact with breast cancer cells to promote EMT in the tumor cells 
[161]. This endows the tumor cells with invasive and migratory phenotypes, therefore, 
enabling the tumor cells to invade the tumor microenvironment and migrate to distal organs 
via the lymphatic system and blood stream. As the mesenchymal CTCs migrate toward 
distal organs, they interact with systemically secreted pro-MET factors that then activate 
the MET cascade. This would include the re-expression of E-cadherin in the CTCs but 
would not affect the mesenchymal phenotype as this phenotype is required for the 
continued migration of the cells to distal organs. Upon arrival at a distal organ, the tumor 
cells could then adhere to the organ via E-cadherin mediated cell-cell adhesion, leading to 
secondary tumor establishment and colonization. This model may help explain MET-
mediated tumor colonization in organs such as the brain or lungs, which are distal to WATs. 
In instances where target organs are proximal to WAT, for example the liver and the bone, 
locally secreted pro-MET factors would also interact with tumor cells to facilitate tumor 
colonization at the organ. The interaction activates the MET pathway, thereby making the 




Figure 4.1: Schematic representation of a conceptual model for adipose tissue-driven 
secondary breast tumor metastasis  
Breast adipocytes interacts with pre-metastatic epithelial tumor cells to promote EMT in 
the tumor cells. EMT of tumor cells results in their acquisition of mesenchymal-like 
properties due to the upregulation of mesenchymal proteins such as vimentin and N-
cadherin and the downregulation of epithelial proteins such as E-cadherin. Mesenchymal 
cancer cells intravasates into the circulatory/lymphatic system where they interact with 
bloodborne pro-MET. This interaction leads to the activation of the MET pathway but does 
not affect epithelial protein expression therefore, resulting in the concomitant expression 
of mesenchymal/epithelial phenotypes (hybrid phenotype) by the circulating tumor cells. 
The hybrid mesenchymal/epithelial cancer cells homes to their target organs where they 




4.6 Conclusion and Future Direction   
Overall, this study revealed that lean and obese mouse WAT can cause MET-like 
changes in mesenchymal TNBC cells via the secretion of an unknown pro-MET factor(s). 
Contrary to my original hypothesis, the MET induction capacity of lean and obese mice 
WAT was not significantly different. However, adipose tissue from the subcutaneous and 
visceral depots affected MET-like changes in TNBC cells differently. The lean and obese 
mouse subcutaneous WAT cause a much stronger MET-like effect in MDA-MB-231 cells 
compared to the lean visceral WAT. However, in the obese state, the visceral WAT induces 
a comparable MET-like effect to the lean and obese subcutaneous WAT. Unfortunately, 
the effects of BMA on the MET of TNBC cells could not be ascertained because the 
methodology that is needed to study this effect requires further optimization. Lastly, this 
study demonstrated that pro-MET factors are systemically secreted in both lean and obese 
states. Serum derived pro-MET factor(s) promote MET-like changes in TNBC cells in the 
same manner, irrespective of the state of adiposity. 
Taken together, findings from this study suggest that WAT derived pro-MET 
factor(s) could potentially play a role in MET dependent in secondary tumor colonization 
in TNBC patients, irrespective of their state of obesity. This means that therapeutic 
inhibition of the factor(s) could be a viable strategy for preventing tumor spread in both 
lean and obese TNBC patients. Future work should focus on the identification and 
characterization of serum and adipose tissue derived pro-MET factor(s) possibly via a 
proteomics or gene expression analysis. In addition, it would be beneficial to explore the 
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mechanisms underlying adipocyte-induced MET-like changes in TNBC cells. 
Identification of the pro-MET factor(s) and its implicated signaling pathways would help 
identify the best approach for therapeutic interventions that would inhibit tumor metastasis. 
Furthermore, future studies may explore efficient models for studying the effect of BMA 
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